Your browser doesn't support javascript.
loading
Uncovering a neurological protein signature for severe COVID-19.
El-Agnaf, Omar; Bensmail, Ilham; Al-Nesf, Maryam A Y; Flynn, James; Taylor, Mark; Majbour, Nour K; Abdi, Ilham Y; Vaikath, Nishant N; Farooq, Abdulaziz; Vemulapalli, Praveen B; Schmidt, Frank; Ouararhni, Khalid; Al-Siddiqi, Heba H; Arredouani, Abdelilah; Wijten, Patrick; Al-Maadheed, Mohammed; Mohamed-Ali, Vidya; Decock, Julie; Abdesselem, Houari B.
Affiliation
  • El-Agnaf O; Neurological Disorders Research Center (NDRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar; College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Bensmail I; Proteomics Core Facility, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Al-Nesf MAY; Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar; Center of Metabolism and Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Road, London NW3 2PF, UK.
  • Flynn J; Illumina Corporation, San Diego, CA, USA.
  • Taylor M; Bioinfo Solutions LLC, Parker, CO, USA.
  • Majbour NK; Neurological Disorders Research Center (NDRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Abdi IY; Neurological Disorders Research Center (NDRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Vaikath NN; Neurological Disorders Research Center (NDRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Farooq A; Aspetar Hospital, Orthopaedic and Sports Medicine, Hospital, FIFA Medical Centre of Excellence, Doha, Qatar.
  • Vemulapalli PB; Proteomics Core, Weill Cornell Medicine - Qatar, Doha, Qatar.
  • Schmidt F; Proteomics Core, Weill Cornell Medicine - Qatar, Doha, Qatar.
  • Ouararhni K; Genomics Core Facility, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Al-Siddiqi HH; College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar; Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Arredouani A; College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar; Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Wijten P; Diabetes Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Al-Maadheed M; Center of Metabolism and Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Road, London NW3 2PF, UK; Anti-Doping Laboratory Qatar, Doha, Qatar.
  • Mohamed-Ali V; Center of Metabolism and Inflammation, Division of Medicine, Royal Free Campus, University College London, Rowland Hill Road, London NW3 2PF, UK; Anti-Doping Laboratory Qatar, Doha, Qatar.
  • Decock J; College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar; Translational Cancer and Immunity Center (TCIC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
  • Abdesselem HB; Neurological Disorders Research Center (NDRC), Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar; College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar; Proteomics Core Facility, Qat
Neurobiol Dis ; 182: 106147, 2023 06 15.
Article de En | MEDLINE | ID: mdl-37178811
ABSTRACT
Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has sparked a global pandemic with severe complications and high morbidity rate. Neurological symptoms in COVID-19 patients, and neurological sequelae post COVID-19 recovery have been extensively reported. Yet, neurological molecular signature and signaling pathways that are affected in the central nervous system (CNS) of COVID-19 severe patients remain still unknown and need to be identified. Plasma samples from 49 severe COVID-19 patients, 50 mild COVID-19 patients, and 40 healthy controls were subjected to Olink proteomics analysis of 184 CNS-enriched proteins. By using a multi-approach bioinformatics analysis, we identified a 34-neurological protein signature for COVID-19 severity and unveiled dysregulated neurological pathways in severe cases. Here, we identified a new neurological protein signature for severe COVID-19 that was validated in different independent cohorts using blood and postmortem brain samples and shown to correlate with neurological diseases and pharmacological drugs. This protein signature could potentially aid the development of prognostic and diagnostic tools for neurological complications in post-COVID-19 convalescent patients with long term neurological sequelae.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: COVID-19 / Maladies du système nerveux Type d'étude: Etiology_studies Limites: Humans Langue: En Journal: Neurobiol Dis Sujet du journal: NEUROLOGIA Année: 2023 Type de document: Article Pays d'affiliation: Qatar

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: COVID-19 / Maladies du système nerveux Type d'étude: Etiology_studies Limites: Humans Langue: En Journal: Neurobiol Dis Sujet du journal: NEUROLOGIA Année: 2023 Type de document: Article Pays d'affiliation: Qatar